Abstract: A method for producing a nucleic acid-encapsulated adeno-associated virus (AAV) hollow particle, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising a sequence for A region and a sequence for D? region in an AAV inverted terminal repeat (ITR) (i.e., an AD sequence) or a sequence complementary to the AD sequence and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into a cell capable of producing an AAV hollow particle; and (3) culturing the cell obtained in step (2).

Abstract: Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: An automatic needle mover (1) for moving a medical threaded needle includes: two shafts (a first shaft (11) and a second shaft (12)) extending in the same direction and slidable relative to each other along a longitudinal direction; a needle holding portion (a second needle support portion (22)) provided on one end side of the second shaft (12); a needle-receiving portion (a first needle support portion (21)) provided on one end side of the first shaft (11); and a handle (30) serving as a control portion for controlling the sliding of the two shafts. The needle holding portion has a first groove portion provided in a first claw portion protruding in a direction intersecting the longitudinal direction of the shafts. The needle-receiving portion has a second groove portion provided in a second claw portion protruding in a direction intersecting the longitudinal direction of the shafts.

Abstract: The present invention provides a therapeutic agent or a prophylactic agent of dementia containing xanthine oxidase inhibitor such as a compound represented in formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof as an active ingredient.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: An object of the present invention is to provide a vector capable of oligodendrocyte-specifically suppressing expression of the PLP1 gene for treating PMD caused by abnormality of the PLP1 gene, and a promoter and miRNA therefor, and a pharmaceutical composition comprising the vector. The oligodendrocyte-specific promoter of the present invention comprises a nucleic acid having a sequence identity of at least 90% to a nucleotide sequence set forth in SEQ ID NO: 1. The miRNA of the present invention specific to the PLP1 gene comprises a pair of nucleotide sequences consisting of a specific antisense sequence and sense sequence.

Abstract: The present invention aims to develop a method capable of evaluating T cell immune function. A method for evaluating T cell immune function including detecting and quantifying soluble PD-L1 having a binding ability to PD-1, and an ELISA system used for detecting and quantifying bsPD-L1, including a carrier with a solid-phased PD-1 protein, a means for reacting the carrier and a test sample, and a means for detecting and m quantifying soluble PD-L1 bound to the carrier as bsPD-L1.

Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.

Abstract: A method of detecting somatic mutations of tumor marker genes includes recovering a peripheral blood mononuclear cell layer from a blood sample collected from a subject and examining whether or not a nucleic acid derived from tumor marker genes having somatic mutations is detected from DNA included in the peripheral blood mononuclear cell layer.

Abstract: The inventors found that postsurgical recurrence and/or metastasis of cancer is suppressed by administering a beta-blocker to a cancer patient during a perioperative period of cancer surgery. Accordingly, the disclosure provides an agent for suppressing recurrence and/or metastasis of cancer, comprising a beta-blocker and being administered during a perioperative period of cancer surgery.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: A method for evaluating a health condition, includes: measuring a test amount of cell free DNA per unit amount of a body fluid sample collected from a subject after tumor resection; and comparing the measured test amount of cell free DNA with a reference value so as to evaluate a health condition of the subject. The reference value is one of a predetermined threshold value; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject before tumor resection; an amount of cell free DNA per unit amount of a body fluid sample collected from the subject between 1 week and 3 months after tumor resection; and an amount of cell free DNA per unit amount of a body fluid sample collected from the subject by the time of collecting the body fluid sample for measuring the test amount of cell free DNA.

Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.

Abstract: A transfection agent is provided that has lower toxicity and can be applied in the clinical setting. The transfection agent comprises a peptide surfactant.

Abstract: The invention provides a method for simple, rapid and inexpensive analysis of drugs such as nicotine and other drugs which are accumulated in biological samples of addictive drugger of tobacco, stimulant drug and the like. The method comprises the steps of introducing the biological sample into an injection needle, inserting the needle into an injector of a chromatograph and injecting a carrier into the needle to conduct chromatography treatment.

Abstract: The invention provides a surgical device for endoscopic surgery having the function of temporarily storing liquid (a first function), the function of keeping a physical space for surgery and a sufficient endoscopic field (a second function), and the function of protecting organs (a third function), and an insertion device for inserting the surgical device into a body. [Solving Means] The surgical device for endoscopic surgery is an inter-organ spacer (10) including liquid holding means (1) formed of a porous soft material having the ability to temporarily store liquid and the ability to retain its shape. The insertion device for inserting the inter-organ spacer into a body includes a tubular holder capable of holding the inter-organ spacer for endoscopic surgery.

Abstract: A biological condition evaluation apparatus determines a symptom of a heart abnormality based on at least one index calculated from a heartbeat interval and/or a pulse interval. The apparatus determines whether it is in a referential period where an amount of change in the index is comparatively small. The apparatus determines whether a plurality of conditions are satisfied or not in an evaluation period set after the referential period. One condition is that an amount of change in the index in the evaluation period is greater than that observed during the referential period. Another condition is that a rate of change in the index is equal to or greater than a predetermined threshold value. The apparatus determines that there is a symptom of a heart abnormality, when both the conditions are satisfied.

Abstract: A living body state monitor apparatus includes: a living body information acquisition device to acquire living body information containing an electrocardiography waveform and a pulse waveform from a user; an irregular heartbeat detection section to detect an irregular heartbeat from the electrocardiography waveform; and a pulse wave feature quantity extraction section to extract a pulse wave feature quantity from a pulse wave corresponding to the irregular heartbeat. Further, a living body state determination section is included to determine a danger degree on user's living body state using both of (A) information on kind and/or continued time period of an irregular heartbeat detected by the irregular heartbeat detection section, and (B) a pulse wave feature quantity extracted by the pulse wave feature quantity extraction section, and/or a variation of the extracted pulse wave feature quantity.

Abstract: A method for treating amyotrophic lateral sclerosis is disclosed wherein a compound having xanthine dehydrogenase inhibiting activity is administered.